School of Nutrition and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
J Investig Allergol Clin Immunol. 2013;23(2):120-4.
Common variable immunodeficiency (CVID) is a heterogeneous group of disorders characterized by decreased serum immunoglobulin levels and increased susceptibility to recurrent bacterial infections. There is increasing evidence that the type 1 helper T cell (T(H)1)/T(H)2 cell balance is shifted towards a T(H) 1-type immune response in patients with CVID. This study was performed to measure levels of soluble CD26 (sCD26) and CD30 (sCD30) as plausible markers of a dysregulated immune response in a group of patients with CVID.
Twenty-five patients with CVID and 20 age- and sex-matched controls were enrolled in this study. A sandwich enzyme-linked immunosorbent assay was used to measure serum sCD26 and sCD30 levels.
The mean (SD) serum sCD26 level was significantly higher in patients with CVID than in controls (88.47 [59.82] ng/mL vs 28.31 [25.61] ng/mL, P = .001). Serum sCD30 levels were also significantly higher in patients with CVID than in controls (196.37 [169.71] ng/mL vs 30.72 [12.98] ng/mL, P < .001). Analysis of serum sCD30 levels in association with different clinical variables indicated that patients with splenomegaly and malignancy had significantly higher levels than patients without these disorders. However, serum sCD30 levels did not differ with bronchiectasis or autoimmunity.
The presence of increased serum levels of sCD26 and sCD30 in patients with CVID suggests that CVID patients have a polarized immune response towards a T(H)1-like phenotype, whereas the association between high levels of these markers and disease severity suggests that the soluble form could be used as a prognostic tool in CVID.
普通变异型免疫缺陷（CVID）是一组以血清免疫球蛋白水平降低和反复发生细菌感染为特征的异质性疾病。越来越多的证据表明，CVID 患者的辅助性 T 细胞 1 型（Th1）/Th2 细胞平衡向 Th1 型免疫反应倾斜。本研究旨在测量一组 CVID 患者可溶性 CD26（sCD26）和 CD30（sCD30）的水平，作为其失调免疫反应的可能标志物。
本研究纳入 25 例 CVID 患者和 20 名年龄和性别匹配的对照者。采用夹心酶联免疫吸附试验测量血清 sCD26 和 sCD30 水平。
CVID 患者的血清 sCD26 水平明显高于对照组（88.47[59.82]ng/ml 比 28.31[25.61]ng/ml，P=.001）。CVID 患者的血清 sCD30 水平也明显高于对照组（196.37[169.71]ng/ml 比 30.72[12.98]ng/ml，P<.001）。分析血清 sCD30 水平与不同临床变量的关系表明，有脾肿大和恶性肿瘤的患者明显高于无这些疾病的患者。然而，血清 sCD30 水平与支气管扩张或自身免疫性疾病无关。
CVID 患者血清中 sCD26 和 sCD30 水平升高表明 CVID 患者存在向 Th1 样表型极化的免疫反应，而这些标志物水平与疾病严重程度之间的关系提示，其可溶性形式可作为 CVID 的预后工具。
